The Impact

The limited compatibility of current oral drug delivery technologies hinders critical elements of early stage product development that produce significant financial and clinical risk in late stage clinical validation. (1) It restricts medicinal chemists to compounds that do not maximize potency and specificity for a given disease target, leading to sub-optimal efficacy and safety, respectively.

It requires formulation scientists to develop multiple "fit for purpose" dosages, testing a multitude of formulations and production techniques that can alter clinical outcomes and cause significant delays to clinical translation and market entry. In contrast, the DPOD platform enables broad exploration of medicinal chemistries and simplifies oral dosage design to facilitate rapid optimization of a commercially viable oral solid dosage early in pre-clinical development. This minimizes time to proof of concept (PoC) and first in human (FIH) data, and corresponding financial and clinical risk, while improving the success rate of clinical translation and outcomes.